Acasti Pharma (TSXV:ACST) 3-Year FCF Growth Rate : 45.50% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma 3-Year FCF Growth Rate?

Acasti Pharma's Free Cash Flow per Share for the three months ended in Dec. 2023 was C$-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 45.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 43.30% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Acasti Pharma was 49.90% per year. The lowest was -25.20% per year. And the median was 15.10% per year.

Competitive Comparison of Acasti Pharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Acasti Pharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acasti Pharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's 3-Year FCF Growth Rate falls into.

Acasti Pharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Acasti Pharma (TSXV:ACST) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Acasti Pharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (TSXV:ACST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

ACST:USA A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.